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Abstract
Background: The tumor suppressor gene p53 (TP53) controls numerous signaling pathways and is frequently
mutated in human cancers. Novel p53 isoforms suggest alternative splicing as a regulatory feature of p53 activity.
Results: In this study we have analyzed mRNA expression of both wild-type and mutated p53 and its respective
∆p53 isoform in 88 tumor samples from breast cancer in relation to clinical parameters and molecular subgroups.
Three-dimensional structure differences for the novel internally deleted p53 isoform ∆p53 have been predicted.
We confirmed the expression of ∆p53 mRNA in tumors using quantitative real-time PCR technique. The mRNA
expression levels of the two isoforms were strongly correlated in both wild-type and p53-mutated tumors, with
the level of the ∆p53 isoform being approximately 1/3 of that of the full-length p53 mRNA. Patients expressing
mutated full-length p53 and non-mutated (wild-type) ∆p53, "mutational hybrids", showed a slightly higher
frequency of patients with distant metastasis at time of diagnosis compared to other patients with p53 mutations,
but otherwise did not differ significantly in any other clinical parameter. Interestingly, the p53 wild-type tumors
showed a wide range of mRNA expression of both p53 isoforms. Tumors with mRNA expression levels in the
upper or lower quartile were significantly associated with grade and molecular subtypes. In tumors with missense
or in frame mutations the mRNA expression levels of both isoforms were significantly elevated, and in tumors
with nonsense, frame shift or splice mutations the mRNA levels were significantly reduced compared to those
expressing wild-type p53.
Conclusion: Expression of p53 is accompanied by the functionally different isoform ∆p53 at the mRNA level in
cell lines and human breast tumors. Investigations of "mutational hybrid" patients highlighted that wild-type ∆p53
does not compensates for mutated p53, but rather may be associated with a worse prognosis. In tumors, both
isoforms show strong correlations in different mutation-dependent mRNA expression patterns.
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The tumor suppressor and transcription factor p53 (TP53)
is a key regulator of cell integrity with impact on cell
cycling, growth, DNA repair, cell cycle arrest, or apoptosis
(see reviews [1-4]). Correct p53 signaling is essential for
preventing tumor growth (see reviews [5-7]). The struc-
ture of the TP53 protein has been studied extensively and
different conserved domains have been identified [8,9]:
the transcription activation domain, the sequence-specific
DNA-binding domain with a subdomain interacting with
the 53bp2 SH3 domain, a non-structured spacer region
containing a bipartite nuclear localization signal, a
tetramerization domain with a nuclear export signal sub-
domain, and a C-terminal domain modulating DNA-
binding [10-12]. The central core domain of p53 is built
of highly conserved anti-parallel beta-sheet scaffolds
assembling two alpha-helical loops interacting with the
grooves in the DNA [13]. The functional unit of p53 is a
tetramer, where the C-terminal ends of two carboxyl-ter-
minal peptides form a dimer, and two dimers assemble to
tetramers [14,15].
Several p53 isoforms have been described, but for most of
them knowledge has been restricted due to unclear func-
tion, their expression only at certain conditions or at very
low levels, or their detection in other organisms than
humans (see reviews [16,17]). Initially, human p53 was
shown to have only one promoter and two alternative
splice forms, p53i9 [18] and ∆40p53 [19-21]. Commonly
p53 alternative splice forms diverge from full-length p53
by altering the N-terminal [19,20,22] or the or the C-ter-
minal domains [18,23], but preserve the central domain.
Recently, a new internal promoter together with four
additional N- and C-terminal isoforms were found [22],
and the first internal splice form ∆p53 was discovered
[24]. The novel alternative splice form ∆p53 is unique due
to its unusual splice sites and expression pattern. In addi-
tion, its activation profile differs from that of p53 [24].
The importance of regulatory features of p53 isoforms has
likely been underestimated [16], in particular, whether
mutations in the p53 gene in tumors have different effect
on the various isoforms. The various functions associated
with the novel p53 alternative splice forms have attracted
attention and opened questions about possible other
functions (see comments [17,25]), since differential
expression of p53 isoforms represents an interesting
option for promoter selectivity, tissue-specific activation,
and selective activation of downstream targeting genes.
The p53 gene has the highest mutation frequency in
human tumors [26,27], with large varieties in the posi-
tions of the alterations and in the mutation spectra due to
environmental, geographical, racial and other factors [28-
31]. Mutations in the p53 gene are found in 20–30% of
breast carcinomas (see reviews [3,28]), most of them
being missense point mutations mainly located in or close
to the conserved DNA-binding region [32]. The p53 muta-
tion status has been shown to be an independent prog-
nostic marker for poor outcome in breast cancer [33,34].
All mutations are "loss-of-function" regarding the tumor
suppressor functions of wild-type p53, but some reports
also describe that at least some mutations exert a novel
"gain of function" (see review [35]).
In this paper we have studied mRNA expression of full-
length p53 and its ∆p53 isoform in both p53 wild-type
and mutant tumors from 88 breast cancer patients. We
used quantitative real-time PCR (qRT-PCR) and related
the mRNA expression levels to clinical and biological
data. We wanted to explore whether patients with muta-
tions affecting both full-length and ∆p53 differ with
respect to clinical and molecular markers from patients
with mutations affecting only the full-length and not the
∆p53 isoform.
Results
Bioinformatic analyses of exon transition, structural 
domain organization, and prediction of three-dimensional 
protein folding for the alternative splice form ∆p53
∆p53 is a novel alternative splice form that differs from
the full-length p53 form by lacking parts of exon 7, com-
plete elimination of exon 8 and partial removal of exon 9
[24]. The uncommon splice mechanism involves two 7
base pair long cassettes with an identical sequence in exon
7 and exon 9, of which one is retained in the isoform (Fig-
ure 1A; for sequence details see Additional file 1). We esti-
mated the splice site plausibility by analyzing the cassette
sequence for exonic splicing enhancer (ESE) motifs using
the ESEfinder [36]. Exonic enhancers are potential bind-
ing sites for splicing factors of the highly conserved serine/
arginine-rich (SR) protein family. The cassette motif gives
a high score (3.5) for the splice factor SF2/ASF protein and
has some similarity with known signal sequences for alter-
native splicing (see review [37]). According to Swiss-Prot/
TrEMBL structural protein domain classification [12] full-
length p53 consists of a transcription activation domain
(aa 1–44), a DNA-binding domain (aa 102–292), an
unstructured spacer containing a bipartite nuclear locali-
zation signal (aa 305–321; a bipartite nuclear localization
signal domain is defined as two adjacent basic amino
acids with a spacer region of any 10 residue and at least
three basic residues (Arg or Lys) in the five positions fol-
lowing the spacer region [38]), a tetramerization domain
(aa 325–356), and a C-terminal regulatory domain (aa
368–387) (Figure 1B). In ∆p53, this domain organization
is modified by the removal of 66 amino acid (residues
257 to 322), which mainly disturbs the DNA-binding
domain, and eliminates the spacer with the bipartite
nuclear localization signal. The DNA-binding domain (aa
102–292) is truncated, but the 53bp2 SH3 domainPage 2 of 20
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localization signal domain (aa 305–321) is entirely
removed.
To elucidate the differences in three-dimensional struc-
ture between p53 and ∆p53 the complete sequences of
p53 and ∆p53 were submitted to predictive CPH-model-
ling using the web-based service of the Technical Univer-
sity of Denmark [39]. The core domains of the proteins
were modelled based on available structures in the data-
base: p53 was predicted from aa 94 to 297 with an identity
of 100% (557.0 bits score) and ∆p53 from aa 94 to 274
with 93.4% identity by a 451.5 bits score. (The removal of
residues 257 to 322 by the ∆p53 specific splice process
changes the position numbers of the ∆p53 predicted pro-
tein relative to the full-length protein: residue 274 in
∆p53 corresponds to 340 in the full-length p53 protein).
The isoforms clearly vary in both their secondary and their
calculated three-dimensional structure, even though the
prediction identity for ∆p53 was limited. The three-
dimensional structure prediction, illustrated by using the
RasMol program (Version 2.7.2.1.1.), reveals a modified
structure for ∆p53 in comparison to p53, resulting in a
position shift of an alpha-helical structure and thus con-
densing the structure (Figure 2). In ∆p53 a major alpha-
helical structure at the C-terminal end is deleted, altering
its further orientation. The structural data are supported
by functional studies in cell lines, where the isoforms have
different transactivation activities for the p21, mdm2, 14-
3-3-sigma, bax and PIG3 promoters [24].
p53 and ∆p53 mutational status in relation to clinical, 
pathological and biological factors
We analyzed the existence and expression of the ∆p53 iso-
form in breast tumors from patients with advanced dis-
ease at the mRNA level and asked whether mutations
present in both isoforms had different effects on clinical
and molecular parameters compared to mutations found
only in the full-length form. These patients have previ-
ously been analyzed by whole genome expression micro-
arrays and grouped according to their expression profile
([40-43] for cohorts A, B and D, and unpublished results
for cohort C). Gel electrophoresis followed by qRT-PCR
confirmed that ∆p53 together with full-length p53 was
present in all tumor samples. Patients with tumors har-
bouring mutations residing inside the spliced out region
of the ∆p53 isoform represented the rare mutational gen-
otype of mutated full-length p53 and wild-type ∆p53 and
were termed "mutational hybrids" (Wild type ∆p53/
Mutant p53 = WtM). These patients where grouped (11
patients) and compared to patients with mutations before
and after the spliced region affecting both isoforms (27
patients), and to patients without mutations (50
patients). Of the 27 tumors with mutations affecting both
isoforms 14 were missense mutations, two were in frame
mutations, one a nonsense mutation, four were splice
mutations, and six had frame shift mutations. (For a full
description of the various mutations see Additional file
2). Based on the mutation type the p53/∆p53 double
mutant group (MM) was further subdivided into the MI
group with missense and in frame mutations, and the MII
group with nonsense, frame shift and splice mutations
(Table 1). Kruskal Wallis rank tests were performed for
differences in clinical and molecular parameters in three
(WtWt-WtM-MM) or four classes (WtWt-WtM-MIMI-
MIIMII) and the Mann-Whitney test was used to test for
independent association between subgroups. A slightly
higher frequency of patients with distant metastasis at
time of diagnosis was observed in the WtM group com-
pared to the MIMI group (p < 0.07). No other significant
differences were observed for the "mutational hybrid"
group weighted against the other groups. We analyzed
whether the "mutational hybrid" genotype had an effect
on patient survival time in a subset of patients from two
prospective studies [44,45] of comparable treatment and
uniformity. In the Kaplan-Meier plot (Figure 3) survival
data for a total of 50 patients without distant metastases
at time of diagnosis are shown. The survival rates in
patients with the "mutational hybrid" genotype (Wt ∆p53
– M p53) was similar to the survival rate in patients with
mutations in both p53 and p53 (M ∆p53 – M p53), and
the survival rates in these two groups were significantly
different compared to patients with wild-type ∆p53 and
p53 (Wt ∆p53 – Wt p53) (p < 0.05).
qRT-PCR analysis of p53 and ∆p53 mRNA expression 
levels using Universal Human Reference cell lines, 
mutated, and non-mutated human breast tumors
Using qRT-PCR, the expression level of both full-length
p53 and ∆p53 mRNA were determined. Both isoforms
were present in the Universal Human Reference of 10
human cell lines mixture and in the human breast tumor
samples. The p53 and ∆p53 mRNA levels were deter-
mined by standard curve measurements in a 1.5 orders of
linear dynamic dilution range performed on the same
plate. Both splice forms showed similar slopes and
accordingly have equivalent target efficiencies (Figure 4).
Under the presupposition of equivalent efficiencies the
Comparative Ct (Cycle threshold) ∆∆Ct method can be
selected to compare normalized expression levels of dif-
ferent samples relative to a calibrator sample.
Using the comparative Ct method we compared the line-
arized (2-∆∆Ct) expression levels of the standard curves of
the two alternative splice forms relative to each other,
whereas for the various tumor samples the more robust
standard curve method was applied. An investigation of
different housekeeping genes revealed two independent
genes, PMM1 and RPL32 [46], suitable for mRNA expres-
sion level determination in human breast tumors (forPage 3 of 20
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Schematic representation of the full-length p53 and the alternative splice form ∆p53Figure 1
Schematic representation of the full-length p53 and the alternative splice form ∆p53. (A) The mRNA structure of 
exons VI to X of the full-length p53 and the ∆p53 isoform are shown. The removed sequence in ∆p53 is located in parts of 
exon VII, in exon VIII, and in a fraction of exon IX. The alternative splice cassette junction sequence, represented twice in the 
full-length p53 and once in the alternative splice form, is indicated in red. (B) Structural organization of the full-length p53 and 
∆p53 and its functional domains. p53 protein domain classification and their locations along the protein according to Swiss-
Prot/TrEMBL [12]. Subdomains of main structures are indicated with various colors. Red lines mark the part eliminated by the 
splicing process of ∆p53 and covering aa 257 to 322 of the DNA-binding domain and the complete non-structured spacer 
region with bipartite nuclear localization signal.
full-length p53 mRNA
∆p53 isoform mRNA
VI VII VIII IX X
VI XVII IX
VI VII VIII IX X
5’ 3’ DNA
CA CTG GA splice cassette
1 44 102 292 305321 325 356 368 387
339350241 248
257 322
AA Pos Domain
1-44 Transcription activation domain
102-292 DNA-binding domain (sequence specific)
241-248 interacts with the 53bp2 SH3 domain
292-325 Unstructured spacer region
305-321 bipartite nuclear localization signal
325-356 Tetramerization domain
339-350 nuclear export signal
368-387 C-terminal DNA-binding regulatory domain
257-322 ∆p53 splicing location and removal
∆p53
B.
N C
A.
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Predicted structural organization of the p53 and ∆p53 core domains illustrated by three-dimensional modelsFigure 2
Predicted structural organization of the p53 and ∆p53 core domains illustrated by three-dimensional models. 
Illustrated are CPH predicted models [39] of the p53 and ∆p53 isoforms using the RasMol program. The p53 core domain of 
204 aa (total length of wild-type p53 is 393 aa) is predicted from aa 94 to 297 with a prediction identity of 100% (557.0 bits 
score) and the ∆p53 core domain is predicted from aa 94 to 274 (total length of ∆p53 is 327 aa) with a 93.4% identity and 
451.5 bits score (protein position 274 in the ∆p53 accordingly corresponds to protein position 340 in the full-length p53). 
Models and prediction structures for p53 (A) and ∆p53 (B) are shown, and the variations are colored by secondary structures 
as follows: alpha helices in magenta, beta sheets in yellow, turns in pale blue, and all other residues are colored white. Differ-
ences between the isoform predictions are indicated with arrows and the N-terminal starting and C-terminal end points are 
marked in the figure. Due to the alternative splicing a major alpha-helical structure is missing in ∆p53 (in A red arrow) and the 
tertiary protein structure of ∆p53 is slightly more compact, as can bee seen from the moved alpha helix, indicated by green 
arrows. Below: uploaded protein core for the three-dimensional structure prediction query and received structural template.
p53 ∆p53
p53 ∆p53
255255
A. B.
(C) 297
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(C) 274 (340)
(N) 94
Score: 451.5 bits
Identity: 93.4 %
Query: 1 SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPP
SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPP
Templ: 1 SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPP
Query: 61 GTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFR
GTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFR
Templ: 61 GTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFR
Query: 121 HSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLDGEYFTLQIRGRERFE
HSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITL+ L GR FE
Templ: 121 HSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLL--GRNSFE
Query: 181 M 181
+
Templ: 181 V 181
Score: 557.0 bits
Identity: 100.0 %
Query: 1 SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPP
SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPP
Templ: 1 SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPP
Query: 61 GTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFR
GTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFR
Templ: 61 GTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFR
Query: 121 HSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVR
HSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVR
Templ: 121 HSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVR
Query: 181 VCACPGRDRRTEEENLRKKGEPHH 204
VCACPGRDRRTEEENLRKKGEPHH
Templ: 181 VCACPGRDRRTEEENLRKKGEPHH 204
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Table 1: Relationship between p53 and ∆p53 mutation status and their correlation to biological and clinical factors
Wild type (Wt)
Wt ∆p53
Wt p53
Mutational hybrid
Wt ∆p53
M p53
Mutations
(MI = MS, IF)
MI ∆p53
MI p53
Mutations
(MII = NS, FS, SP, 
SC)
MII ∆p53
MII p53
Characteristic Total No. No. of 
patients
(%) No. of 
patients
(%) No. of 
patients
(%) No. of 
patients
(%)
Lymph node status 88 Node-negative 16 32.0 1 9.1 4 23.5 6 60.0
Node-positive 34 68.0 10 90.9 13 76.5 4 40.0
Estrogen receptor 
status
88 Negative 10 20.0 3 27.3 8 47.1 3 30.0
Positive 40 80.0 8 72.7 9 52.9 7 70.0
Progesterone 
receptor status
88 Negative 13 26.0 4 36.4 9 52.9 6 60.0
Positive 37 74.0 7 63.6 8 47.1 4 40.0
ERBB2/HER status 60 Negative 29 80.6 5 62.5 10 90.9 1 20.0
Positive 7 19.4 3 37.5 1 9.1 4 80.0
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WtWt-WtM1 n.s.
WtM-MIMI1 n.s. (p < 0.07)
WtM-MM1 n.s.
WtWt-WtM-MM2 n.s.
WtWt-WtM-MIMI-MIIMII2 n.s.
WtWt-WtM1 n.s.
WtM-MIMI1 n.s.
WtM-MM1 n.s.
WtWt-WtM-MM2 p < 0.03
WtWt-WtM-MIMI-MIIMII2 p < 0.05
WtWt-WtM1 n.s.
WtM-MIMI1 n.s.
WtM-MM1 n.s.
WtWt-WtM-MM2 n.s.
WtWt-WtM-MIMI-MIIMII2 n.s.
WtWt-WtM1 n.s. (p < 0.08)
WtM-MIMI1 n.s.
WtM-MM1 n.s.
WtWt-WtM-MM2 p < 0.008
WtWt-WtM-MIMI-MIIMII2 p < 0.02
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Distant metastisis 
at time of diagnosis
65 Negative 30 90.9 7 77.8 15 100.0 7 87.5
Positive 3 9.1 2 22.2 0 0.0 1 12.5
Grade 88 1 5 10.0 0 0.0 0 0.0 0 0.0
2 24 48.0 4 36.4 4 23.5 4 40.0
3 21 42.0 7 63.6 13 76.5 6 60.0
Response to 
chemotherapy
54 Response 24 92.3 8 88.9 9 81.8 5 62.5
None response 2 7.7 1 11.1 2 18.2 3 37.5
Subgroups* 84 Luminal A 25 53.2 2 18.2 2 12.5 0 0.0
Luminal B 6 12.8 2 18.2 4 25.0 3 30.0
ERBB2 7 14.9 3 27.3 4 25.0 4 40.0
Basal 4 8.5 4 36.4 6 37.5 2 20.0
Normal-like 5 10.6 0 0.0 0 0.0 1 10.0
MS = missense mutations, NS = nonsense mutations, FS = frame shift mutations, IF = in frame mutations, SP = splice mutations, SC = ∆p53 splice cassette mut
M = MI + MII
1 for WtWt-WtM, WtM-MIMI and WtM-(MIMI+MIIMII) the Mann-Whitney test was performed
2 for WtWt-WtM-(MIMI+MIIMII) and WtWt-WtM-MIMI-MIIMII the Kruskal Wallis test was performed
* The tumors have previously been subjected to whole genome microarray analysis and classified into subgroups according to their expression profile (see Mat
Table 1: Relationship between p53 and ∆p53 mutation status and their correlation to biological and clinical factors (Continued)
Molecular Cancer 2006, 5:47 http://www.molecular-cancer.com/content/5/1/47details see Material and Methods). Repeated experiments
showed that standard curves for full-length p53 mRNA
intercept at 27.01, while ∆p53 had a Ct intercepting at
28.41 (Figure 4). The comparative Ct value ∆∆Ct is given
as the Ct intercept difference between the two isoform
standard curves for ∆Ct(p53) = 27.01 and ∆Ct(∆p53) =
28.41, with a value of -1.40. Accordingly, ∆p53 is
expressed 2.64 times lower (2-∆∆Ct = 2.64) relative to the
full-length p53 isoform.
Comparison of the mRNA levels of the two isoforms p53
and ∆p53 in 88 tumors samples revealed a high correla-
tion in both mutated and non-mutated tumors with a cor-
relation coefficient of r2 = 0.86 for wild-type and r2 = 0.85
for mutant tumors, respectively (Figure 5A and 5B). The
expression levels of ∆p53 mRNA in the two tumor sam-
ples with in frame (FU27), or with a frame shift (FU08)
mutation located in the splice cassette were very low (Fig-
ure 6), further confirming the existence of ∆p53 in the
other human tumor samples.
Interestingly, the expression level of both mutant and
wild-type p53 varied by more than 3-fold for both full-
length and ∆p53, and the different mutation types
showed a large variation in mRNA expression for both iso-
forms (Figure 6). Tumors with wild-type p53 have an aver-
age mRNA expression level of 0.770 arbitrary units (a.u.),
tumors with missense or in frame mutations (MI) showed
elevated mRNA abundance of 1.310 a.u., while nonsense,
frame shift or splice mutations (MII) had lower mRNA
levels with an average of 0.496 a.u. (Figure 7 and Table 2).
The wild-type p53 isoform mRNA level were significantly
different (p < 0.00002) from the levels in both mutation
groups and the same was the case for the mRNA level of
the ∆p53 isoforms (p < 0.004) (Figure 7 and Table 2).
mRNA expression levels of mutated and non-mutated 
human p53 and ∆p53 in human breast tumors in relation 
to clinical and biological parameters
The wild-type full-length p53 mRNA expression levels dis-
play a wide range. We explored whether mRNA expression
levels were associated with particular clinical and/or
molecular parameters. Therefore, we divided the wild-
type p53 mRNA expression profiles into three classes of
quartiles, merging the two midst quartiles to one group:
(Q1) <25%, (Q2&Q3) 25–75% and (Q4) >75%. Kruskal
Wallis tests were used to analyze for differences between
the three groups and the Mann-Whitney test was used for
tests for differences between any two groups (Table 3).
Molecular breast cancer subtype distribution was signifi-
cantly different among the various p53 mRNA expression
groups (p < 0.03). The Luminal A subtype is dominating
in the majority of the middle and high expression group,
while tumors with low wild-type p53 mRNA expression
have a low proportion of Luminal A tumors (9.1%) and a
high fraction of the Luminal B and ERBB2 subgroups.
Middle quartiles were showing the highest fractions of
estrogen receptor positive tumors (96%) compared to
only 69% and 62% in the low expression (Q1) and high
expression quartiles (Q4), respectively (p < 0.03). Similar
observations were made for the progesterone receptor sta-
tus. Low wild-type p53 mRNA expression was signifi-
cantly associated with grade 3 tumors in Q1, while Q2/Q3
and Q4 in their majority were of grade 2 (p < 0.003). No
significant association was found for age, menopausal sta-
tus, lymph node status, ERBB2/HER status, tumor histol-
ogy, or p53 LOH. For the ∆p53 wild-type distribution our
analysis of expression quartiles revealed similar associa-
tions for biological and clinical parameters (data not
shown).
We then looked for the relationship between the various
molecular subgroups and mutation classes in both p53
and ∆p53 (Table 4). The Luminal A subtype is signifi-
cantly overrepresented (47%) in patients with wild-type
∆p53 tumors compared to patients with MI (13%) or MII
(0%) mutations (p < 0.04). In tumors with MI type muta-
tions the Basal subgroup was dominating (40%) and in
Kaplan-Meier plot of survival rates for patients with mutated and u mutated full-length p53 nd ∆p53Figure 3
Kaplan-Meier plot of survival rates for patientswith 
mutated and unmutated full-length p53 and ∆p53. 
Cumulative breast cancer survival for a subset of patients 
(50) is shown for three groups of patients, depending on 
their mutational status of p53 versus ∆p53: patients with 
wild-type ∆p53 and wild-type p53 (Wt ∆p53 – Wt p53; n = 
24), "mutational hybrid" patients with non-mutated (wild-
type) ∆p53 and mutated full-length p53 (Wt ∆p53 - M p53; n 
= 7), and patients with mutations in ∆p53 and p53 (M ∆p53 – 
M p53; n = 19); the significance is p = 0.0498.
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Molecular Cancer 2006, 5:47 http://www.molecular-cancer.com/content/5/1/47tumors with MII mutations the ERBB2 subtype (46%) was
most highly represented (Table 4).
Beside mutational status and despite relatively low num-
bers of tumor samples, the mRNA expression levels for
both p53 and ∆p53 mRNA mutant and wild-type demon-
strated interesting results: The Luminal A subtype revealed
scattered p53 mRNA expression levels in wild-type p53,
but rather high mRNA expression in the mutated p53
tumors, while the Luminal B subtype had either a very low
or very high mRNA expression rate in the wild-type p53,
but normal expression distribution in mutant p53
tumors. The ERBB2 molecular breast cancer subtype indi-
cates low p53 mRNA levels in mutant p53, but normal
scattering in wild-type p53 tumor samples (Figure 6).
Association rank tests were performed, scoring wild-type
and the different mutation types of the ∆p53 isoform in
relation to various clinical, pathological and biological
factors [see Additional file 3]. In contrast to full-length
p53 (Table1), we observed a significant lower fraction of
patients with lymph node positive tumors in the ∆p53
MII group compared to the Wt and MI group. ∆p53 iso-
form shows associations for the same parameters and sim-
ilar to the observed associations for full-length p53 [see
Additional file 3].
Discussion
Recently, several new p53 isoforms have been detected,
but their functional roles, particular in tumorigenesis,
remain unclear and require further investigations (see per-
spective [17]). ∆p53 is one of these novel isoforms, it
arises by an uncommon alternative splice mechanism,
exhibits a p53-independent transcriptional activity, and a
gene activation pattern different from that of p53 in cell
lines [24]. Recently, it was shown that cells from patients
with acute myeloid leukemia induction of chemotherapy
modulates the p53/∆p53 protein ratio pattern [47].
In this study we have investigated ∆p53 in-silico and at
the mRNA expression level in relation to wild-type and
mutated full-length p53 in order to determine possible
correlations to biological and clinical parameters in
human breast tumors. Our bioinformatic analysis
revealed a high score for exonic splicing enhancers for the
cassette sequence motif. We performed three-dimensional
predictions for the structure of the ∆p53 isoform, and con-
firmed its mRNA expression in human tumors. Although
the model prediction identity for ∆p53 was lower than for
p53, we were able to identify that a major alpha-helical
structure is missing at the C-terminal end, changing the
further orientation of the protein resulting in a more com-
pacted structure. These structural changes may explain the
inability of ∆p53 to form hetero-tetramers with full-
length p53, and the different transcriptional activity of
∆p53 independent from full-length p53 [24]. Activity dif-
ferences have also been observed in other p53 isoforms:
The ∆40p53 isoform is not activated in response to geno-
toxic stress [19], p53i9 is defective in transcriptional activ-
ity [18], and the p53AS isoform in mice displays different
DNA-binding efficiencies [48].
The three-dimensional predictions and the functional
analysis of ∆p53 in cell lines encouraged us to investigate
∆p53 function in relation to full-length p53 in human
tumors. The special alternative splice process removes all
Table 2: p53 or ∆p53 relative mRNA expression
Wild type (Wt) Mutation group I (MI)
missense and in frame 
mutations
Mutation group II (MII)
nonsense, frame shift and 
splice mutations
No. of 
patients
Mean a.u. 
(± SEM)
Median
No. of 
patients
Mean a.u. 
(± SEM)
Median
No. of 
patients
Mean a.u. 
(± SEM)
Median
Groups p
full-length 
p53
50 0.770 (± 
0.059)
27 1.310 (± 
0.116)
11 0.496 (± 
0.100)
Wt-MI-MII1 p < 0.00002
Wt-MI2 p < 0.0002
0.753 1.159 0.357 Wt-MII2 p < 0.04
MI-MII2 p < 0.002
∆p53 61 0.790 (± 
0.061)
15 1.171 (± 
0.162)
11 0.482 (± 
0.101)
Wt-MI-MII1 p < 0.004
Wt-MI2 p < 0.04
0.725 0.974 0.310 Wt-MII2 p < 0.02
MI-MII2 p < 0.002
Mean is given in relative expression in arbitrary units (a.u.)
1 for Wt-MI-MII the Kruskal Wallis test was performed
2 for Wt-MI, WT-MII and MI-MII the Mann-Whitney test was performedPage 9 of 20
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Molecular Cancer 2006, 5:47 http://www.molecular-cancer.com/content/5/1/47mutations inside the spliced-out sequence and, as a con-
sequence, the mutational statuses of the tumors are
affected differentially for p53 than for ∆p53. These "muta-
tional hybrid" tumors have a mutated full-length p53 and
a non-mutated ∆p53. We investigated whether patients
containing "mutational hybrid" tumors had biological
and clinical parameters different from other types of
mutations. No significant differences to specific changes
in survival rate, in clinical or biological parameters were
observed, although a slightly higher frequency of patients
with distant metastasis at time of diagnosis was found.
Thus, wild-type ∆p53 does not seem to compensate for
mutated p53, but possibly exerts adverse effects in tumors
expressing mutant p53. One may speculate that a correct
balance between full-length p53 and ∆p53 is required to
full-fill specific patterns in control of cell-cycle regulation
p53 and ∆p53 standard curve by qRT-PCRFigure 4
p53 and ∆p53 standard curve by qRT-PCR. Standard curve plotting showing CO (concentration) in log scale versus Ct 
(Cycle threshold). The fluorescence signal of the reporter dye (FAM) subtracted by the baseline signal of the passive reference 
dye (ROX) results in a ratio defined as the normalized reporter signal ∆Rn. ∆Rn increases with accumulating PCR cycles until 
it reaches a plateau. Ct represents the fractional cycle number at which significant increase in Rn above a baseline signal of the 
passive reference dye (ROX) can be detected. Standard curve points are based on serially diluted cDNAs of a mixture of 10 
human cancer cell lines in a 1,5 orders of linear dynamic range. All samples were performed in triplets. Red quadrates illustrate 
data for p53 standard curve; blue squares show data for ∆p53 standard curve of the same template. The red line linear repre-
sents regression of the standard quantity and the CT value for ∆p53 and green line stand for linear regression of the standard 
quantity and the CT value for p53. The comparative Ct value between the two standard curves is 1.40.
∆p53 standard
slope: -3.55
Intercept: 28.41
R2: 0.99
p53 standard
slope: -3.73
Intercept: 27.01
R2: 0.99
∆∆Ct = ∆Ct(p53) - ∆Ct(∆p53) = -1.40
∆p53 relative to p53 = 2–∆∆Ct = 2.64
C
t
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Correlation between mRNA expression level of full-length p53 and ∆p53 in relation to different molecular breast cancer sub-types in A. wild-type p53 tumors or B. p53-mutated tumorsFigure 5
Correlation between mRNA expression level of full-length p53 and ∆p53 in relation to different molecular 
breast cancer subtypes in A. wild-type p53 tumors or B. p53-mutated tumors. Both wild-type samples (A) and 
mutated samples (B) show a wide range of mRNA expression in a.u. (arbitrary units) with significant association to molecular 
breast cancer subtypes. Note that the spreading is different in the two groups with a more continuously spreading in the wild-
type tumors compared to the mutated onces. Samples are marked by their molecular subtype characteristics: Luminal A (dark 
blue), Luminal B (light blue), ERBB2 (red), Basal (pink), Normal-like (green) and without information (black). Horizontal lines 
illustrate borders between the quartiles for wild-type (25% = 0.452; 50% = 0.754 and 75% = 1.022) or mutants (25% = 0.569; 
50% = 0.956 and 75% = 1.584). The regression line for all samples is drawn with an equation y = 0.789x + 0.100 and a regres-
sion coefficient of 0.86 for wild-type and y = 0.973x - 0.049 and a regression coefficient of 0.85 for the mutant samples.
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Molecular Cancer 2006, 5:47 http://www.molecular-cancer.com/content/5/1/47and thus influences the overall survival in patients with a
disturbed ∆p53/p53 phenotype. Since this dataset is
small, larger cohorts are necessary to confirm these find-
ings.
Full-length p53 and ∆p53 mRNA expression levels were
measured by qRT-PCR. We could confirm that ∆p53
mRNA is expressed in a mixture of different human cancer
cell lines and in tumors, with ∆p53 being expressed at a
lower level than full-length p53. The mRNA levels of the
two isoforms p53 and ∆p53 are highly correlated. A 25–
30% reduction in expression levels has also been reported
for the mouse ASp53 isoform [49]. It may be a general fea-
ture that N- or C-terminal end truncated isoforms rather
modulate p53 functions than abrogate it completely [16].
The existence of ∆p53 mRNA is further confirmed by the
observation that an in frame mutation located in the
splice cassette led to high full-length p53 but reduced
∆p53 mRNA expression, distinguishable from all others
in frame or missense mutations. These and other results
from different isoforms [22] form a picture according to
which full-length p53 is the most highly expressed form
during genotoxic stress.
In a series of 88 advanced primary breast tumors we inves-
tigated whether certain clinical parameters are related
with the expression patterns of p53 and ∆p53. It has pre-
viously been shown [22] that various p53 isoforms are
expressed in human breast tumors, but correlation of
expression levels to clinical data or mutational status was
missing in that study. Steady-state amounts of mRNAs in
genes related to breast cancer have very rarely been meas-
Correlation between mRNA expression level of full-length p53 versus ∆p53 in breast carcinomas with various p53 mutationsFigure 6
Correlation between mRNA expression level of full-length p53 versus ∆p53 in breast carcinomas with various 
p53 mutations. p53 and ∆p53 mRNA expression levels of mutated p53 in human breast tumors are shown with p53 relative 
mRNA expression in a.u. (arbitrary units) on x-axis and ∆p53 on y-axis. Different mutation types are indicated by various sym-
bols. "Mutational hybrids", mutations represented on full-length p53, but removed in ∆p53, are marked with open symbols. 
Mutations present in both isoforms are specified with filled symbols. The shape of the symbols indicate the various mutation 
types: ■,  missense mutations,  in frame mutations, ▲,  nonsense mutations, * frame shift mutations, ● splice mutations, 
- mutations in the splice cassette (the two samples full-filling this criteria are highlighted with their sample ID). Horizontal lines 
show borders between the median values of the relative mRNA expression subgroups: MII vs Wt vs MI. The regression line for 
missense mutations is drawn with an equation y = 1.03x - 0.12 and a regression coefficient of 0.89. (1 low p53 value in this sam-
ple might be due to mutation in p53 primer binding site, 2 low ∆p53 value in this sample might be due to mutation in ∆p53 
primer binding site – for details see Additional file 2).
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Molecular Cancer 2006, 5:47 http://www.molecular-cancer.com/content/5/1/47ured [50]. In the examined breast tumors we recognized
for both p53 and ∆p53 that the different mutation types
show particular mRNA expression patterns. In compari-
son to wild-type mRNA expression, tumors with missense
and in frame mutations had significantly increased
amounts of mRNA, while in tumors with nonsense, frame
shift and splice mutations mRNA levels were significantly
reduced for both isoforms. Our study is thus one of the
first confirming that mRNA expression of both the full-
length p53 and the ∆p53 form are elevated in tumors with
missense and in frame mutations. The high level of p53
protein seen in mutated tumors has previously been
explained by accumulation of the protein due to lack of
degradation of the mutated protein and not by overex-
pression at the mRNA level. After DNA damage p53 is acti-
vated and Mdm2-p53 interaction decreases [4,51]. In a
situation with increased levels of mutated p53, the dis-
turbed dynamics of this fine-balance may result in an
unsatisfied request for functional p53 activity inside the
cell.
The molecular breast cancer subtypes [41,42] differ signif-
icantly with respect to frequencies of p53 mutations. The
majority of wild-type tumors is classified as Luminal A
subtype, while the majority of tumors with missense and
in frame mutations belong to the Basal subtype and the
ERBB2 subtype has mainly nonsense, frame shift or splice
mutations. The different subgroups have different survival
with the poorest survival rates for the class with highest
p53 mutation rate [33,43,52].
We observed that the expression of full-length wild-type
p53 was widely scattered, despite the significant differ-
ences between mutation groups as described above. To
explore this unexpected result we divided the tumors into
four p53 wild-type expression groups by quartiles. The
tumors in the lowest quartile group were significantly
associated with estrogen-negative receptor staining, high
grade and the Luminal B and ERBB2 breast cancer sub-
types, while tumors in the two middle quartiles showed
significant association with a high fraction to estrogen
receptor positive tumors, low grade and tumors of the
Luminal A subtype. Tumors in the highest quartile of p53
abundance were associated with negative estrogen recep-
tor status, low grade and the Luminal A breast cancer sub-
type. These findings are interesting and warrant further
investigations in order to elucidate the molecular basis for
these expression "extremes" in the wild-type p53 gene.
Explanations may comprise technical reasons, like diffi-
culties in detection of all types of mutations by standard
Histogram of p53 and ∆p53 relative mRNA expressionFigure 7
Histogram of p53 and ∆p53 relative mRNA expression. Mean and SEM of the relative p53 and ∆p53 mRNA expression 
in a.u. (arbitrary units) for the different mutation classes: missense, in frame, nonsense, frame shift, splice or splice cassette 
(splice cass). p53 and ∆p53 mRNA expression levels are proportion adjusted according to the comparative Ct of 2.64. The 
number of cases (n) is given by 1 for p53 and by 2 for ∆p53, respectively. Differences in case numbers for p53 and ∆p53 are due 
to some mutations which are located inside the area, but removed by the alternative splicing process of ∆p53. The expression 
level for both full-length p53 and ∆p53 between the various mutational classes were highly significant (Table 2).
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Molecular Cancer 2006, 5:47 http://www.molecular-cancer.com/content/5/1/47techniques, or a biological basis due to mutations in genes
other than p53 itself, disrupting the p53-signaling path-
way. Future studies with an enlarged cohort size are
required to determine whether the different distributions
of low and high p53 mRNA level in the molecular sub-
groups are the cause or effect of the tumor.
Conclusion
The tumor suppressor and transcription factor p53 is
accompanied by different alternative splice forms. In sil-
ico analysis indicate three-dimensional and functional
differences of the ∆p53 and full-length p53 isoforms.
Quantitative real-time PCR confirmed ∆p53 mRNA
expression with strong correlation between the two iso-
forms, however, with 2.64 higher levels for the p53 full-
length form, both in mutated and non-mutated tumors. If
at all, "mutational hybrid" patients had a slightly worse
prognosis than patients with p53 mutations in both iso-
forms, indicating that wild-type ∆p53 does not replace the
p53 function lost by mutation, but rather might exert an
adverse effect. The mRNA expression of p53 and ∆p53
level showed a wide range in p53 wild-type tumors, with
significant association to molecular breast cancer subtype
distribution. In tumors, different mutation-dependent
mRNA expression patterns were found with significant
higher mRNA expression of both isoforms from missense
or in frame p53 mutated genes compared to the wild-type
p53 gene. A significant association was found for the dis-
tribution of breast cancer subtypes for wild-type and
mutated ∆p53 and the scattering of p53 mRNA expression
levels revealed differences in wild-type p53 or mutated
p53 tumors among the various subtypes.
Materials and methods
Patients
A total of 88 breast tumors samples from patients with
advanced disease were selected from 4 different cohorts
(A, B, C, and D): Fifty-six of the patients were part of a pro-
spective study at the Haukeland University Hospital Ber-
gen (Norway) on locally advanced breast cancer (T3/T4
Table 3: Relationship between wild-type full-length p53 mRNA expression level and clinical, pathological and biological factors
wild-type full-length p53 RNA level
Q1 (<25%) Q2 & Q3 (25–75%) Q4 (>75%)
Characteristic Total No. Total (%) No. of 
patients
(%) No. of 
patients
(%) No. of 
patients
(%) Groups p
Estrogen 
receptor status
Negative 10 20 4 30.8 1 4.2 5 38.5 Q1-Q2/3-Q41 p < 0.03
Positive 40 80 9 69.2 23 95.8 8 61.5 Q1-Q2/32 p < 0.03
Q1-Q42 n.s.
Q2/3-Q42 p < 0.009
Progesterone 
receptor status
Negative 13 26 3 23.1 3 12.5 7 53.8 Q1-Q2/3-Q41 p < 0.03
Positive 37 74 10 76.9 21 87.5 6 46.2 Q1-Q2/32 n.s.
Q1-Q42 n.s.
Q2/3-Q42 p < 0.009
ERBB2/HER 
status
Negative 29 80.6 9 75.0 13 86.7 7 77.8 Q1-Q2/3-Q41 n.s.
Positive 7 19.4 3 25.0 2 13.3 2 22.2 Q1-Q2/32 n.s.
Q1-Q42 n.s.
Q2/3-Q42 n.s.
Grade 1 5 10.0 0 0.0 2 8.3 3 23.1 Q1-Q2/3-Q41 p < 0.003
2 24 48.0 2 15.4 15 62.5 7 53.8 Q1-Q2/32 p < 0.003
3 21 42.0 11 84.6 7 29.2 3 23.1 Q1-Q42 p < 0.003
Q2/3-Q42 n.s.
Subgroups Luminal A 25 53.2 1 9.1 18 75.0 6 50.0 Q1-Q2/3-Q41 p < 0.007
Luminal B 6 12.8 3 27.3 0 0.0 3 25.0 Q1-Q2/32 p < 0.003
ERBB2 7 14.9 3 27.3 3 12.5 1 8.3 Q1-Q42 p < 0.05
Basal 4 8.5 2 18.2 1 4.2 1 8.3 Q2/3-Q42 n.s.
Normal-like 5 10.6 2 18.2 2 8.3 1 8.3
1 for Q1-Q2/3-Q4 the Kruskal Wallis test was performed
2 for Q1-Q2/3 the Mann-Whitney test was performed
2 for Q1-Q4 the Mann-Whitney test was performed
2 for Q2/3-Q4 the Mann-Whitney test was performedPage 14 of 20
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Molecular Cancer 2006, 5:47 http://www.molecular-cancer.com/content/5/1/47and/or N2 tumors). Of these, thirty patients (A) received
adjuvant doxorubicin monotherapy [44] and twenty-six
patients (B) received adjuvant 5-fluorouracil and mitomy-
cin treatment [45] before surgery. Twenty-three breast car-
cinoma specimens (C) were obtained from patients
surgically treated at the National Cancer Institute of Milan
(Italy) in 2002 ([53] and unpublished). Nine breast
tumor samples (D) were from a series of patient samples
sequentially collected at Ullevål University Hospital (Nor-
way) from 1990–94 [54]. All breast carcinoma samples
were frozen immediately after surgery and stored at -70°C
to -80°C. Total RNA was isolated from snap frozen tumor
tissue using TRIzol® solution (Invitrogen™). The concen-
tration of total RNA was determined using an HP 8453
spectrophotometer (Hewlett Packard) and the integrity of
the RNA was assessed using a 2100 Bioanalyzer (Agilent)
for series C and D.
Mutation analysis
Mutation analysis of p53 was performed by pre-screening
exon 2–11 using Temporal Temperature Gradient Gel
Electrophoresis (TTGE), as described elsewhere [55], fol-
lowed by sequencing. Previous mutation screening of
these patients revealed 50 tumors with wild-type full-
length p53, whereas in the other 38 tumors 25 missense
mutations, 2 nonsense mutations, 6 frame shift, 2 in
frame mutations and 3 splice mutations were detected
([33,44,45,53], for summary see Additional file 2).
Biological and clinical factors
The estrogen receptor (ER) and progesterone receptor
(PR) status were analyzed using both immunohistochem-
istry (IHC) and biochemical/ligand-binding assay
(Abbott Diagnostics). Lymph node status, grade, and dis-
tant metastasis at time of diagnosis were available for
patients in cohorts A, B and D, ERBB2/HER status were
available for patients in cohorts A and D, and response to
chemotherapy were available for patients in cohorts A and
B [33,44,45]. For patients in cohort C, the lymph node
status and histological grade were obtained from histolog-
ical reports. Hormone receptors status and ERBB2/HER
status were performed using IHC and scored using a semi-
quantitative evaluation. Age, menopausal status, lymph
node status, tumor histology, or p53 LOH were available
for patients in all cohorts ([44,45,53,54] and unpub-
lished). Breast cancer subtype classification was based on
variation in gene expression derived from microarray
experiments. Each sample was assigned to its subclass by
the correlation to the centroid for the subclass [43]. Breast
cancer subtype assignment for patients in the cohorts A, B,
and D have previously been published [40-43] and are
unpublished for patients in cohort C.
Quantitative real time PCR (qRT-PCR)
RT and qPCR reaction
RT-reaction was performed using the GeneAmp® RNA PCR
kit from Applied Biosystems. A 20 µl reaction contained 4
µl 25 mM MgCl2 solution, 2 µl 10× PCR Buffer II, 1 µl
H2O, premixed Deoxyribonucleoside triphospahtes: 2 µl
dGTP, 2 µl dATP, 2 µl dTTP, 2 µl dCTP (10 mM each), 1
µl RNase Inhibitor (20 U/µl), 1 µl Random hexamers and
1 µl MuLV Reverse Transcriptase (50 U/µl) as a master
mix, and 2 µl of total RNA was added prior to reaction
start. Based on a previous photometric measurement the
Table 4: p53 or ∆p53 mutant classes and their relation to molecular subgroups*
Wild type (Wt) Mutation group I (MI)
missense and in frame 
mutations
Mutation group II (MII)
nonsense, frame shift 
and splice mutations
No. of 
patients
(%) No. of 
patients
(%) No. of 
patients
(%) Groups p
full-length p53 Luminal A 25 53.2 4 15.4 0 0.0 Wt-MI-MII1 p < 0.006
Luminal B 6 12.8 6 23.1 3 27.3 Wt-MI2 p < 0.02
ERBB2 7 14.9 7 26.9 4 36.4 Wt-MII2 p < 0.008
Basal 4 8.5 9 34.6 3 27.3 MI-MII2 n.s.
Normal-like 5 10.6 0 0.0 1 9.1 Wt-MI&MII2 p < 0.002
∆p53 Luminal A 27 46.6 2 13.3 0 0.0 Wt-MI-MII1 p < 0.04
Luminal B 8 13.8 4 26.7 3 27.3 Wt-MI2 n.s. (p < 0.07)
ERBB2 10 17.2 3 20.0 5 45.5 Wt-MII2 p < 0.03
Basal 8 13.8 6 40.0 2 18.2 MI-MII2 n.s.
Normal-like 5 8.6 0 0.0 1 9.1
1 for WT-MI-MII the Kruskal Wallis test was performed
2 for WT-MI the Mann-Whitney test was performed
* The tumors have previously been subjected to whole genome microarray analysis and classified into subgroups according to their expression 
profile (see Material and Methods)Page 15 of 20
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Molecular Cancer 2006, 5:47 http://www.molecular-cancer.com/content/5/1/47total RNA template concentration was below the reaction
capacity of ≤1 µg RNA per reaction. Adapted times and
temperature profiles for the reverse transcription were
used:Incubation for 10 min at 25°C, 30 min at 42°C for
reverse transcription of RNA, 5 min at 95°C for denatura-
tion and 5 min at 5°C to cool down the reaction. For each
series of cDNA reactions negative controls were added to
insure contamination free consumables for the RT-reac-
tion. After the RT-reaction samples were diluted 1:4 to get
a final concentration of about 10 ng/µl cDNA.
qPCR reaction
qPCR reaction was done in a final volume of 25 µ contain-
ing 12,5 µl TaqMan® Universal PCR Master Mix (Applied
Biosystems, contains 2× AmpliTaq Gold® DNA Polymer-
ase, AmpErase® UNG, dNTPs (with dUTP), Passive Refer-
ence 1, and optimized buffer components with
proprietary formulation), 6,75 µl H2O, 1,25 µl (18 µM)
forward primer, 1,25 µl (18 µM) reverse primers, and 1,25
µl (5 µM) probe (following producers recommended con-
centrations of 900 nM for primers and 250 nM for the
probe). The reaction was put in an ABI PRISM® 96-Well
Optical Reaction Plate placed on ice before 2 µl of the
diluted cDNA template (approx. 10 ng/µl) was added. In
a series of pre-experiments this concentration had turned
out as the lowest amount required producing reliable and
reproducible results in a reaction. The standard thermal
cycling conditions of initial 50°C 2 min and 95°C 10 min
followed by 40 cycles at 95°C for 15 s and 60°C for 1 min
were used. All reactions were performed using an ABI
PRISM® 7000 Sequence Detection System (TaqMan®).
Experiments were performed in triplets for the standard
curve and duplicates for all data points. Each qPCR reac-
tion included no-template controls and five points of the
standard curve in 1.5 orders of linear dynamic dilution
range. For the standard curve a commercially available
Universal Human Reference RNA (Stratagene, La Jolla,
USA) was used consisting of equal amounts of RNA from
10 different human cancer cell lines. Analysis settings for
threshold and the Comparative Ct (Cycle threshold) were
set to auto and adjusted manually, if necessary.
Analytical Method
Briefly, in real time PCR the exponential increase in fluo-
rescence signal during cycling is measured to generate a
quantitative relation to the target amount at reaction start.
Two analytical methods are established for qRT-PCR
measurement, the standard curve method and the com-
parative Ct method (∆∆Ct). The benefit of the standard
curve method is its independence of variations in amplifi-
cation efficiencies between different genes, different splice
variants, or between the target gene and the endogenous
controls. The comparative Ct method was used to com-
pare the linearized (2-∆∆Ct) expression levels of the stand-
ard curves of the two alternative splice forms relative to
each other, whereas for the various tumor samples the
more robust standard curve method was applied.
Primer and probes
Primers and probes for the p53 and ∆p53 mRNA sequence
were designed with the assistance of the Primer Express®
software (Applied Biosystems). We tested several primer
pairs, highest specificity for ∆p53 was reached with a for-
ward primer covering exon 7, the splice cassette and the
exon 9 junction. For the full-length p53 the forward
primer covers the exon 6/7 junction, respectively. The
sequence of the various primers were:
p53: TP53 C1S8-FP 5-GCCCCCAGGGAGCACTA-3;
TP53 C1S8-RP 5-GGGAGAGGAGCTGGTGTTG-3;
TP53 C1S8-PP 5-FAM-TTGGGCAGTGCTCGCT-MGB-3.
∆p53: TP53 E6/7c-FP 5-TGAGGTTGGCTCTGACTGTACC-
3;
delta TP53 E7/9c-RP 5-CTCCATCCAGTGTGATGATGGT-
3;
delta TP53-PP 5-FAM-GCAGGAACTGTTACACATG-MGB-
3.
pmm1: PMM1-FP 5-ATCAACTTCTGCCTCAGCTACATG-
3;
PMM1-RP 5-CCATTCCGGAACTCGATGA-3;
PMM1-PP 5-FAM-AGGTTCCACGCTTCT-MGB-3 (modi-
fied after [46]).
rpl32: RPL32-FP 5-ACCAGTCAGACCGATATGTCAAAA-3;
RPL32-RP 5-TTGTCAATGCCTCTGGGTTTC-3;
RPL32-PP 5-FAM-CGCCAGTTACGCTTAA-MGB-3 (modi-
fied after [46]).
Endogenous control
A general problem for gene expression measurements
using qRT-PCR is to adjust for differences in loading, PCR
inhibition or degradation. Photometric measurements are
unreliable for sensible methods like qRT-PCR, as they do
not take into account differences in the RT-reaction or
changes in the mRNA/total RNA ratio. Many technical
papers and reviews have addressed the problem of proper
endogenous control genes for the normalization of qRT-
PCR performance [46,56-61]. However, these studies
show often contradictory results and do not come up with
a "golden rule". We have carefully investigated most of thePage 16 of 20
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18S ribosomal RNA (18S), β-actin, cyclophilin, glyceral-
dehydes-3-phosphatase dehydrogenase (GAPDH), β2-
microglobulin, β-glucronidase (GUS), hypoxanthine
ribosyl transferase (HPRT), and the transcription factor
IID TATA binding protein (TBP). We have rejected most of
these commonly used endogenous controls based on the
existence of retropseudogenes for some of these genes (β-
actin, GADH, HPRT [62-64]) or on their previous
observed tumor or cancer type specific expression altera-
tion patterns (β-actin, GAPDH, TBP, cyclophilin
[58,60,65-67]). Especially GAPDH correlates with clinical
and molecular parameters in human breast cancer and
should not be used as control RNA [68]. We followed the
recommendation of [60] to use at least two endogenous
controls. Based on the investigations of [46,59,61], and
our own survey of these genes in microarray experiments,
we choose the two endogenous controls LP32 and PMM1
for this study. The traditional loading control 18S rRNA
was included as reference to previous studies and thus,
low, medium and highly expression ranges were covered
by our endogenous controls. However, 18S rRNA is over-
expressed in mammary gland and colon cancer [66,69],
affected by various biological factors and drugs [70,71],
and shows an imbalance between mRNA and the rRNA
content in mammalian mammary tumors [72]. Compari-
son of expression variation in our study showed that the
highest divergence was found for 18S and consequently it
was omitted. All relative mRNA quantity values of p53
and ∆p53 were normalized to the average levels of the two
independent endogenous control references PMM1 and
RPL32.
Software applications and statistical analysis
p53 protein domain classification and their locations
along the protein were specified according to Swiss-Prot/
TrEMBL [12]. Exonic splicing enhancers (ESEs) binding
sites for splicing factors of the serine/arginine-rich (SR)
protein family were analyzed using the ESEfinder software
[36]. For three-dimensional structural prediction the com-
plete sequences of p53 and ∆p53 were submitted to the
CPHmodels 2.0 server [73], a web-based CPH-modeling
service of the Technical University of Denmark [39]. The
bits scores of the model prediction indicate the precision
of a match to a HMM profile. Alignments scores are com-
monly reported as bits scores: The likelihood that the
query sequence is a plausible homologue of the database
sequence is compared to the likelihood that the sequence
was instead generated by a "random" model. The log2 of
this likelihood ratio gives the bits score. The three-dimen-
sional structure prediction models were illustrated using
the RasMol program (Win Molecular Graphics Windows
Version 2.7.2.1.1.). For survival and all other statistical
analysis the software package SPSS® for Windows (Release
12.0.2, 24 Mar 2004; Copyright ®SPSS Inc.) was used. Dif-
ferences between mutant groups, in clinical or molecular
parameters were analyzed using the Kruskal Wallis rank
tests for k independent samples and the Mann-Whitney
test for independent association analysis between any two
subgroups. Breast cancer survival was analyzed by the log-
rank test and illustrated as Kaplan-Meier plots.
Competing interests
The author(s) declare no financial or non-financial com-
peting interests.
Authors' contributions
LOB carried out the structural in silico analysis and the
qRT-PCR studies including primer design and analysis;
LOB further performed all data analysis, writing of the
manuscript, including preparations of all figures and
tables.
SM carried out parts of the qRT-PCR studies.
AL carried out RNA preparation, p53 mutation analysis
and provision of molecular and clinical data for Ullevål
University Hospital cohort.
AB carried out RNA preparation, p53 mutation analysis
and provision of molecular and clinical data for National
Cancer Institute of Milan cohort.
SBG carried out tumor preparation and provision of
molecular and clinical data for doxorubicin and 5-fluor-
ouracil and mitomycin cohorts from the Haukeland Uni-
versity Hospital Bergen.
PEL was responsible for collection of material and lab per-
formance at the Haukeland University Hospital Bergen,
critical reading of the draft.
WD suggested this study and participated in its design,
critical reading of the manuscript.
ID discovered the ∆p53 isoform, provided its sequence
and cell line based data for approval in human breast
tumors, critical reading of the draft.
A-LB-D conceived the study, and participated in its design
and coordination and helped to draft the manuscript.
All authors read and approved the final manuscript.
Accession Numbers
p53 [EMBL: AF307851, HGNC: 11998, PIR: A25224,
Swiss-Prot: P04637, RefSeq: NM_000546, Ensembl:
ENSG00000141510].Page 17 of 20
(page number not for citation purposes)
Molecular Cancer 2006, 5:47 http://www.molecular-cancer.com/content/5/1/47pmm1 (phosphomannomutase 1) [NCBI: U86070,
D87810, HSU86070, SwissProt: Q92871, RefSeq:
NM_002676, Ensembl: ENSG00000100417].
rpl32 (ribosomal protein L32) [NCBI: X03342, SwissProt:
P62910, RefSeq: NM_000994, Ensembl:
ENSG00000144713].
Additional material
Acknowledgements
The present study was supported by The National Programme for 
Research in Functional Genomics in Norway (FUGE) in The Research 
Council of Norway (research grant no. 151911 to LOB and A-LB-D), and 
by EC FP6 funding (grant no. 502983 to WD and A-LB-D). This publication 
reflects the authors' views and not necessarily those of the EC. The Com-
munity is not liable for any use that may be made of the information con-
tained herein. We wish to thank Ole Christian Lingjærde at the 
Bioinformatics Group, Department of Informatics, University of Oslo for 
valuable help and discussion during the statistical analysis.
References
1. Kim E, Deppert W: The complex interactions of p53 with tar-
get DNA: we learn as we go.  Biochem Cell Biol 2003, 81:141-150.
2. May P, May E: Twenty years of p53 research: structural and
functional aspects of the p53 protein.  Oncogene 1999,
18:7621-7636.
3. Sengupta S, Harris CC: p53: traffic cop at the crossroads of
DNA repair and recombination.  Nat Rev Mol Cell Biol 2005,
6:44-55.
4. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network.  Nature
2000, 408:307-310.
5. el Deiry WS: Regulation of p53 downstream genes.  Semin Can-
cer Biol 1998, 8:345-357.
6. Guimaraes DP, Hainaut P: TP53: a key gene in human cancer.
Biochimie 2002, 84:83-93.
7. Wahl GM, Linke SP, Paulson TG, Huang LC: Maintaining genetic
stability through TP53 mediated checkpoint control.  Cancer
Surv 1997, 29:183-219.
8. Hainaut P, Wiman K, Eds: 25 Years of p53 Research Dordrecht, The
Netherlands: Springer; 2005. 
9. Soussi T, Caron dF, May P: Structural aspects of the p53 protein
in relation to gene evolution.  Oncogene 1990, 5:945-952.
10. Kim E, Deppert W: Transcriptional activities of mutant p53:
when mutations are more than a loss.  J Cell Biochem 2004,
93:878-886.
11. Kim E, Deppert W: The versatile interactions of p53 with DNA:
when flexibility serves specificity.  Cell Death Differ 2006,
13:885-889.
12. Swiss-Prot/TrEMBL Feature aligner   [http://www.expasy.org/
cgi-bin/aligner?P04637]
13. el Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B: Defi-
nition of a consensus binding site for p53.  Nat Genet 1992,
1:45-49.
14. Jeffrey PD, Gorina S, Pavletich NP: Crystal structure of the
tetramerization domain of the p53 tumor suppressor at 1.7
angstroms.  Science 1995, 267:1498-1502.
15. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pav-
letich NP: Structure of the MDM2 oncoprotein bound to the
p53 tumor suppressor transactivation domain [comment].
Science 1996, 274:948-953.
16. Courtois S, de Fromentel CC, Hainaut P: p53 protein variants:
structural and functional similarities with p63 and p73 iso-
forms.  Oncogene 2004, 23:631-638.
17. Mills AA: p53: link to the past, bridge to the future.  Genes Dev
2005, 19:2091-2099.
18. Flaman JM, Waridel F, Estreicher A, Vannier A, Limacher JM, Gilbert
D, Iggo R, Frebourg T: The human tumour suppressor gene p53
is alternatively spliced in normal cells.  Oncogene 1996,
12:813-818.
19. Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U,
Oren M, Hainaut P: DeltaN-p53, a natural isoform of p53 lack-
ing the first transactivation domain, counteracts growth sup-
pression by wild-type p53.  Oncogene 2002, 21:6722-6728.
20. Ghosh A, Stewart D, Matlashewski G: Regulation of human p53
activity and cell localization by alternative splicing.  Mol Cell
Biol 2004, 24:7987-7997.
21. Yin Y, Stephen CW, Luciani MG, Fahraeus R: p53 Stability and
activity is regulated by Mdm2-mediated induction of alterna-
tive p53 translation products.  Nat Cell Biol 2002, 4:462-467.
22. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodi-
mas DP, Saville MK, Lane DP: p53 isoforms can regulate p53
transcriptional activity.  Genes Dev 2005, 19:2122-2137.
23. Matlashewski G, Pim D, Banks L, Crawford L: Alternative splicing
of human p53 transcripts.  Oncogene Res 1987, 1:77-85.
24. Rohaly G, Chemnitz J, Dehde S, Nunez AM, Heukeshoven J, Deppert
W, Dornreiter I: A novel human p53 isoform is an essential ele-
ment of the ATR-intra-S phase checkpoint.  Cell 2005,
122:21-32.
25. Prives C, Manfredi JJ: The continuing saga of p53–more sleep-
less nights ahead.  Mol Cell 2005, 19:719-721.
26. Caron dF, Soussi T: TP53 tumor suppressor gene: a model for
investigating human mutagenesis.  Genes Chromosomes Cancer
1992, 4:1-15.
27. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig
E, Smith-Sorensen B, Montesano R, Harris CC: Database of p53
gene somatic mutations in human tumors and cell lines.
Nucleic Acids Res 1994, 22:3551-3555.
28. Børresen-Dale AL: TP53 and breast cancer.  Hum Mutat 2003,
21:292-300.
29. Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ, Hainaut
P: New approaches to understanding p53 gene tumor muta-
tion spectra.  Mutat Res 1999, 431:199-209.
Additional File 1
mRNA and aa sequence of p53 and ∆p53. p53 mRNA and its translated 
protein sequence. The untranslated precursor and untranslated region 
afterwards are illustrated with yellow highlights. Alternating exons are 
written in consecutive black and blue and translation codon triplets are 
marked with alternating white and light yellow. The removed alternative 
splice sequence of ∆p53 is shown with light blue colour and the alternative 
splice cassettes are indicated with red. Sequence information is based on 
ENSEMBL notification [74].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-5-47-S1.pdf]
Additional File 2
p53 and ∆p53 mutation specifications. This table lists the coded patient 
sample IDs, mutation classifications for p53 and ∆p53 (including codon, 
nucleotides and aa changes), incidents of flagging primers and the 
numeric qRT-PCR expression levels.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-5-47-S2.pdf]
Additional File 3
Relationship between ∆p53 status and the standard clinical, patholog-
ical and biological factors. The data provided represent the relationship 
between ∆p53 status and the standard clinical, pathological and biological 
factors.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-5-47-S3.pdf]Page 18 of 20
(page number not for citation purposes)
Molecular Cancer 2006, 5:47 http://www.molecular-cancer.com/content/5/1/4730. Olivier M, Hainaut P: TP53 mutation patterns in breast can-
cers: searching for clues of environmental carcinogenesis.
Semin Cancer Biol 2001, 11:353-360.
31. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P: The
IARC TP53 database: new online mutation analysis and rec-
ommendations to users.  Hum Mutat 2002, 19:607-614.
32. Walker DR, Bond JP, Tarone RE, Harris CC, Makalowski W, Boguski
MS, Greenblatt MS: Evolutionary conservation and somatic
mutation hotspot maps of p53: correlation with p53 protein
structural and functional features.  Oncogene 1999, 18:211-218.
33. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet
C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, Uhrhammer
N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka
C, Hainaut P, Borresen-Dale AL: The clinical value of somatic
TP53 gene mutations in 1,794 patients with breast cancer.
Clin Cancer Res 2006, 12:1157-1167.
34. Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J: TP53 muta-
tion is an independent prognostic marker for poor outcome
in both node-negative and node-positive breast cancer.  Acta
Oncol 2000, 39:327-333.
35. van Oijen MG, Slootweg PJ: Gain-of-function mutations in the
tumor suppressor gene p53.  Clin Cancer Res 2000, 6:2138-2145.
36. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR: ESEfinder: A
web resource to identify exonic splicing enhancers.  Nucleic
Acids Res 2003, 31:3568-3571.
37. Ladd AN, Cooper TA: Finding signals that regulate alternative
splicing in the post-genomic era.  Genome Biol 2002,
3:reviews0008.1-0008.16.
38. PROSITE documentation   [http://expasy.org/prosite/
PDOC00015]
39. Lund O, Nielsen M, Lundegaard P, Worning P: CPHmodels 2.0:
X3M a Computer Program to Extract 3D Models [abstract].
CASP5 conference 2002.
40. Langerod A: Molecular Profiling of Breast Cancer – From sin-
gle gene variants to whole genome expression patterns.  In
PhD thesis University of Oslo, Faculty of Medicine; 2005. 
41. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack
JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A,
Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Bot-
stein D: Molecular portraits of human breast tumours.  Nature
2000, 406:747-752.
42. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie
T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC,
Brown PO, Botstein D, Eystein LP, Borresen-Dale AL: Gene expres-
sion patterns of breast carcinomas distinguish tumor sub-
classes with clinical implications.  Proc Natl Acad Sci USA 2001,
98:10869-10874.
43. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S,
Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE,
Brown PO, Borresen-Dale AL, Botstein D: Repeated observation
of breast tumor subtypes in independent gene expression
data sets.  Proc Natl Acad Sci USA 2003, 100:8418-8423.
44. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lille-
haug JR, Akslen LA, Borresen-Dale AL: Influence of TP53 gene
alterations and c-erbB-2 expression on the response to
treatment with doxorubicin in locally advanced breast can-
cer.  Cancer Res 2001, 61:2505-2512.
45. Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA,
Anker G, Lonning PE: TP53 gene mutations predict the
response to neoadjuvant treatment with 5-fluorouracil and
mitomycin in locally advanced breast cancer.  Clin Cancer Res
2003, 9:5582-5588.
46. Hamalainen HK, Tubman JC, Vikman S, Kyrola T, Ylikoski E, War-
rington JA, Lahesmaa R: Identification and validation of endog-
enous reference genes for expression profiling of T helper
cell differentiation by quantitative real-time RT-PCR.  Anal
Biochem 2001, 299:63-70.
47. Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjert-
sen BT: A distinct p53 protein isoform signature reflects the
onset of induction chemotherapy for acute myeloid leuke-
mia.  Clin Cancer Res 2006, 12:3985-3992.
48. Kulesz-Martin MF, Lisafeld B, Huang H, Kisiel ND, Lee L: Endog-
enous p53 protein generated from wild-type alternatively
spliced p53 RNA in mouse epidermal cells.  Mol Cell Biol 1994,
14:1698-1708.
49. Han KA, Kulesz-Martin MF: Alternatively spliced p53 RNA in
transformed and normal cells of different tissue types.  Nucleic
Acids Res 1992, 20:1979-1981.
50. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Maz-
oyer S: The nonsense-mediated mRNA decay pathway trig-
gers degradation of most BRCA1 mRNAs bearing
premature termination codons.  Hum Mol Genet 2002,
11:2805-2814.
51. Lahav G, Rosenfeld N, Sigal A, Geva-Zatorsky N, Levine AJ, Elowitz
MB, Alon U: Dynamics of the p53-Mdm2 feedback loop in indi-
vidual cells.  Nat Genet 2004, 36:147-150.
52. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan
Y, Hall P, Klaar S, Liu ET, Bergh J: An expression signature for p53
status in human breast cancer predicts mutation status,
transcriptional effects, and patient survival.  Proc Natl Acad Sci
USA 2005, 102:13550-13555.
53. Kringen P, Bergamaschi A, Due EU, Wang Y, Tagliabue E, Nesland JM,
Nehman A, Tonisson N, Borresen-Dale AL: Evaluation of arrayed
primer extension for TP53 mutation detection in breast and
ovarian carcinomas.  Biotechniques 2005, 39:755-761.
54. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen AL: Rela-
tionship between abnormal p53 protein and failure to
express p21 protein in human breast carcinomas.  J Pathol
1997, 181:140-145.
55. Sorlie T, Johnsen H, Vu P, Lind GE, Lothe R, Borresen-Dale AL:
Mutation screening of the TP53 gene by temporal tempera-
ture gradient gel electrophoresis.  In Methods in Molecular Biology
Volume 291. Edited by: Keohavong P, Grant SG. Totowa, NJ: Humana
Press Inc; 2005:207-216. 
56. Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A: Val-
idation of housekeeping genes for normalizing RNA expres-
sion in real-time PCR.  Biotechniques 2004, 37:112-119.
57. Lossos IS, Czerwinski DK, Wechser MA, Levy R: Optimization of
quantitative real-time RT-PCR parameters for the study of
lymphoid malignancies.  Leukemia 2003, 17:789-795.
58. Schmittgen TD, Zakrajsek BA: Effect of experimental treatment
on housekeeping gene expression: validation by real-time,
quantitative RT-PCR.  J Biochem Biophys Methods 2000, 46:69-81.
59. Thellin O, Zorzi W, Lakaye B, De Borman B, Coumans B, Hennen G,
Grisar T, Igout A, Heinen E: Housekeeping genes as internal
standards: use and limits.  J Biotechnol 1999, 75:291-295.
60. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De
Paepe A, Speleman F: Accurate normalization of real-time
quantitative RT-PCR data by geometric averaging of multi-
ple internal control genes.  Genome Biol 2002, 3:RESEARCH0034.
61. Warrington JA, Nair A, Mahadevappa M, Tsyganskaya M: Compari-
son of human adult and fetal expression and identification of
535 housekeeping/maintenance genes.  Physiol Genomics 2000,
2:143-147.
62. Bieche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R, Vidaud
M: Quantitation of MYC gene expression in sporadic breast
tumors with a real-time reverse transcription-PCR assay.
Cancer Res 1999, 59:2759-2765.
63. Gibson UE, Heid CA, Williams PM: A novel method for real time
quantitative RT-PCR.  Genome Res 1996, 6:995-1001.
64. Sellner LN, Turbett GR: The presence of a pseudogene may
affect the use of HPRT as an endogenous mRNA control in
RT-PCR.  Mol Cell Probes 1996, 10:481-483.
65. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth
T, Swinkels DW, Span PN: Normalization of gene expression
measurements in tumor tissues: comparison of 13 endog-
enous control genes.  Lab Invest 2005, 85:154-159.
66. Gerard CJ, Andrejka LM, Macina RA: Mitochondrial ATP syn-
thase 6 as an endogenous control in the quantitative RT-PCR
analysis of clinical cancer samples.  Mol Diagn 2000, 5:39-46.
67. White RJ: RNA polymerase III transcription and cancer.  Onco-
gene 2004, 23:3208-3216.
68. Revillion F, Pawlowski V, Hornez L, Peyrat JP: Glyceraldehyde-3-
phosphate dehydrogenase gene expression in human breast
cancer.  Eur J Cancer 2000, 36:1038-1042.
69. Mullen CA: Review: analogies between trophoblastic and
malignant cells.  Am J Reprod Immunol 1998, 39:41-49.
70. Spanakis E: Problems related to the interpretation of autora-
diographic data on gene expression using common constitu-
tive transcripts as controls.  Nucleic Acids Res 1993, 21:3809-3819.Page 19 of 20
(page number not for citation purposes)
Molecular Cancer 2006, 5:47 http://www.molecular-cancer.com/content/5/1/47Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
71. Warner JR: The economics of ribosome biosynthesis in yeast.
Trends Biochem Sci 1999, 24:437-440.
72. Solanas M, Moral R, Escrich E: Unsuitability of using ribosomal
RNA as loading control for Northern blot analyses related to
the imbalance between messenger and ribosomal RNA con-
tent in rat mammary tumors.  Anal Biochem 2001, 288:99-102.
73. CPHmodels 2.0 Server   [http://www.cbs.dtu.dk/services/CPH
models/]
74. Ensembl Transcript Report
[http:www.ensembl.orHomo_sapiens/transview?tran
script=ENST00000269305&db=core&show=peptide&number=on]Page 20 of 20
(page number not for citation purposes)
